Acurx Pharmaceuticals
ACXP
32 hedge funds and large institutions have $1.33M invested in Acurx Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 8 increasing their positions, 9 reducing their positions, and 1 closing their positions.
800% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 1
33% more funds holding
Funds holding: 24 → 32 (+8)
14% more call options, than puts
Call options by funds: $33K | Put options by funds: $29K
0.24% less ownership
Funds ownership: 0.79% → 0.56% (-0.24%)
2% less capital invested
Capital invested by funds: $1.36M → $1.33M (-$33.4K)
11% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 9
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$434K |
| 2 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
+$28.2K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$28.1K |
| 4 |
Renaissance Technologies
New York
|
+$24.6K |
| 5 |
OBGC
O'Brien Greene & Co
Media,
Pennsylvania
|
+$24.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$790K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$155K |
| 3 |
PFS
Prospect Financial Services
Melville,
New York
|
-$28.1K |
| 4 |
BlackRock
New York
|
-$13.3K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$10.1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Simplex Trading
Chicago,
Illinois
| $3K | +$2.21K | +274 | +391% |
|
|
TRCT
27
Tower Research Capital (TRC)
New York
| $2.12K | -$105 | -13 | -6% |
|
|
CPG
28
Cornerstone Planning Group
Fairfield,
New Jersey
| $850 | -$1.28K | -159 | -95% |
|
29
Bank of America
Charlotte,
North Carolina
| $689 | +$491 | +61 | +871% |
|
|
SFA
30
Semmax Financial Advisors
Winston Salem,
North Carolina
| $684 | -$2.21K | -274 | -97% |
|
|
31
BlackRock
New York
| $615 | -$13.3K | -1,652 | -96% |
|
|
SS
32
SBI Securities
Tokyo,
Japan
| $145 | – | – | – |
|
33
JP Morgan Chase
New York
| – | -$11 | -1 | Closed |
|
ACXP Hedge Fund Activity: Q2 2025 in Review
32 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Acurx Pharmaceuticals (ACXP) for Q2 2025, worth a combined $1.33M — down 2.4% from $1.36M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new ACXP positions and 1 closed out — a net gain of 8 holders — while 8 added to existing stakes and 9 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $434K. The largest seller was Sabby Management, cutting an estimated $790K.
- 32 institutional investors held Acurx Pharmaceuticals (ACXP) as of Q2 2025, up from 24 in Q1 2025.
- Funds reported $1.33M of Acurx Pharmaceuticals stock for Q2 2025, down 2.4% quarter-over-quarter.
- 9 funds opened new Acurx Pharmaceuticals positions in Q2 2025 and 1 closed out, a net change of +8 holders.
- The largest Acurx Pharmaceuticals buyer in Q2 2025 was Armistice Capital, an estimated $434K added.
- The largest Acurx Pharmaceuticals seller in Q2 2025 was Sabby Management, an estimated $790K sold.
Based on aggregated 13F filings for Q2 2025.